Valneva's COVID-19 Vaccine Hopes Almost Over Before They Start
Europe Slashes Supply Deal
Rather than terminating a deal for the French biotech's VLA2001 vaccine, the European Commission has put in a tiny order of 1.25 million doses which could bring the curtain down on Valneva's COVID-19 programs.
You may also be interested in...
The French firm has suspended the manufacturing of its COVID-19 vaccine, instead emphasizing its hopes in advanced Lyme disease and Chikungunya.
Pfizer will invest in partner Valneva’s late-stage Lyme disease jab program, providing much-needed financial support to the French firm which has suffered COVID-19 vaccine sales setbacks.
Less than a year after signing a major advance purchase agreement to supply its inactivated COVID-19 jab to the EU, Valneva is faced with a termination that could hit its 2022 guidance.